Company Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States.
The company’s lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers.
In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment.
It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, Georgia Research Foundation, and MSD International GmbH.
PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.
| Country | United States |
| Founded | 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Frank Bedu-Addo |
Contact Details
Address: 303A College Road East Princeton, New Jersey 08540 United States | |
| Phone | 800 208 3343 |
| Website | pdsbiotech.com |
Stock Details
| Ticker Symbol | PDSB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1472091 |
| CUSIP Number | 70465T107 |
| ISIN Number | US70465T1079 |
| Employer ID | 26-4231384 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kirk V. Shepard M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 6, 2026 | 8-K | Current Report |
| Sep 22, 2026 | 8-K | Current Report |
| Sep 21, 2026 | SCHEDULE 13D | Filing |
| Sep 21, 2026 | 8-K | Current Report |
| Sep 14, 2026 | 8-K | Current Report |
| Sep 8, 2026 | 8-K | Current Report |
| Sep 4, 2026 | 8-K | Current Report |
| Aug 25, 2026 | 8-K | Current Report |
| Aug 19, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 8-K | Current Report |